[{"orgOrder":0,"company":"Betagenon","sponsor":"Ivy Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"O304","moa":"Pan-AMPK","graph1":"Endocrinology","graph2":"Phase II","graph3":"Betagenon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Betagenon \/ Ivy Capital","highestDevelopmentStatusID":"8","companyTruncated":"Betagenon \/ Ivy Capital"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Protein Sciences Corporation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Diamyd","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Protein Sciences Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Diamyd Medical AB \/ Protein Sciences Corporation"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Primary endpoints of safety and tolerability were met in Phase II clinical trial GADinLADA, in which diabetes vaccine Diamyd (GAD-alum) was administered directly into lymph node of 14 patients aged 30 to 70 years with autoimmune form of diabetes called L...

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          July 07, 2022

                          Lead Product(s) : GAD-alum,Vitamin D

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The clinical Phase II trial GADinLADA, where the diabetes vaccine Diamyd® is administered directly into the lymph node in patients with the autoimmune form of diabetes LADA, is fully recruited, and the first results from the trial are planned to be anno...

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          September 04, 2021

                          Lead Product(s) : GAD-alum,Vitamin D

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The patients, diagnosed with type 1 diabetes, have been given the diabetes vaccine Diamyd® directly into the lymph node on three occasions, one month apart, in combination with oral vitamin D (or its placebo) during four months, starting 30 days prior t...

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          May 21, 2021

                          Lead Product(s) : GAD-alum,Vitamin D

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : All 50 patients who participated in the extension of Diamyd Medical's Phase IIb trial DIAGNODE-2 with the diabetes vaccine Diamyd® have now made their 24-month visit, and data will be presented in early July.

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          April 29, 2021

                          Lead Product(s) : GAD-alum,Vitamin D

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Icon Plc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The trial is designed to confirm the effect and safety of Diamyd® in individuals recently diagnosed with type 1 diabetes who carry the genetic HLA DR3-DQ2 haplotype.

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          April 03, 2021

                          Lead Product(s) : GAD-alum,Vitamin D

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase...

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          March 29, 2021

                          Lead Product(s) : GAD-alum,Vitamin D

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Results from the phase IIb trial DIAGNODE-2 with intralymphatic administration of Diamyd® and meta-analysis comprising data from more than 600 patients treated with Diamyd® showing treatment effect in individuals carrying the HLA DR3-DQ2 haplotype, wil...

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          February 26, 2021

                          Lead Product(s) : GAD-alum,Vitamin D

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The results support a precision medicine approach with Diamyd® where significant effect on the preservation of endogenous insulin producing capacity and improved blood glucose control was seen in individuals that carry a specific genotyp, HLA DR3-DQ2.

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          February 06, 2021

                          Lead Product(s) : GAD-alum,Vitamin D

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The immunological findings indicate early treatment-specific immune responses that may associate with HLA type and clinical treatment response to Diamyd®.

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          December 19, 2020

                          Lead Product(s) : GAD-alum

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Diamyd Medical's Phase IIb trial DIAGNODE-2 with the diabetes vaccine Diamyd is expected to present Topline results at the end of September. All patients in the trial where Diamyd® is given directly into the lymph node have completed their 15-month vis...

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          July 13, 2020

                          Lead Product(s) : GAD-alum

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank